Sorafenib-Induced Tuberculosis Reactivation
暂无分享,去创建一个
M. Teo | D. Power | S. O'Reilly | T. O'Connor
[1] C. Porta,et al. Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies? , 2011, Journal of Cancer.
[2] O. Mir,et al. Reactivation of tuberculosis during temsirolimus therapy , 2011, Investigational New Drugs.
[3] C. Porta,et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. , 2010, European journal of cancer.
[4] C. Leung,et al. Tuberculosis in the global aging population. , 2010, Infectious disease clinics of North America.
[5] JoAnne L. Flynn,et al. Understanding Latent Tuberculosis: A Moving Target , 2010, The Journal of Immunology.
[6] F. Mayer,et al. The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro1 , 2009, The Journal of Immunology.
[7] P. Postmus,et al. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia , 2009, European Respiratory Journal.
[8] P. Meylan,et al. Peritoneal tuberculosis after imatinib therapy. , 2009, Archives of internal medicine.
[9] Edwin P Hui,et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Noelke,et al. MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib , 2009, Molecular Cancer Therapeutics.
[11] P. Brossart,et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.
[12] J. Yim,et al. Solid‐organ malignancy as a risk factor for tuberculosis , 2008, Respirology.
[13] R. Song,et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation , 2008, Leukemia.
[14] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[15] E. Waclawski. Osteonecrosis of the jaw and bisphosphonates , 2006, BMJ : British Medical Journal.
[16] B. Lane,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[17] L. Duck,et al. Osteonecrosis of the jaw and bisphosphonates. , 2005, The New England journal of medicine.
[18] R. Horsburgh,et al. Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.
[19] D. Karnak,et al. Reactivation of Pulmonary Tuberculosis in Malignancy , 2002, Tumori.
[20] V. Ribrag,et al. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. , 2001, The New England journal of medicine.
[21] John Chan,et al. Tuberculosis: Latency and Reactivation , 2001, Infection and Immunity.